Analysed PRAXIS PRECISION MEDICINES I (PRAX:NASDAQ) News Sources
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
04-06-2026
yahoo.com
Praxis Precision Medicines (PRAX) Stock After Mixed POWER1 Trial Results How Does The Valuation Stack Up
15-06-2026
yahoo.com
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
22-06-2026
yahoo.com
Praxis Precision Medicines Gains After FDA Grants Breakthrough Therapy Designation
22-06-2026
advfn.com
Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies
29-06-2026
yahoo.com
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02-07-2026
yahoo.com
What is the current price of PRAXIS PRECISION MEDICINES I (PRAX:NASDAQ)?
The current price of PRAXIS PRECISION MEDICINES I (PRAX:NASDAQ) is $324.99.
PRAXIS PRECISION MEDICINES I (PRAX:NASDAQ) absolute price change since previous trading day?
The absolute price change of PRAXIS PRECISION MEDICINES I (PRAX:NASDAQ) since the previous trading day is $-8.13.
PRAXIS PRECISION MEDICINES I (PRAX:NASDAQ) percentage price change since previous trading day?
The percentage price change of PRAXIS PRECISION MEDICINES I (PRAX:NASDAQ) since the previous trading day is -2.4406%.
What is the most recent average sentiment score for PRAXIS PRECISION MEDICINES I (PRAX:NASDAQ)?
The most recent average sentiment score for PRAXIS PRECISION MEDICINES I (PRAX:NASDAQ) is 75 out of 100.
What is the most recent average sentiment for PRAXIS PRECISION MEDICINES I (PRAX:NASDAQ)?
The most recent sentiment for PRAXIS PRECISION MEDICINES I (PRAX:NASDAQ) is .
SEC-8K** Filing Available For PRAXIS PRECISION MEDICINES I (PRAX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.